You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫藥(600056.SH):注射用頭孢他啶通過一致性評價
格隆匯 05-13 15:40

格隆匯5月13日丨中國醫藥(600056.SH)宣佈,近日,公司下屬全資子公司海南通用三洋藥業有限公司(簡稱“通用三洋”)獲得國家藥監局核准簽發的三份注射用頭孢他啶《藥品補充申請批准通知書》,該藥品通過仿製藥質量和療效一致性評價。

注射用頭孢他啶屬於第三代頭孢菌素類抗生素。對大腸埃希菌、肺炎桿菌等腸桿菌科細菌和流感嗜血桿菌、銅綠假單胞菌等有高度抗菌活性,對硝酸鹽陰性桿菌、產鹼桿菌等亦有良好抗菌作用,可用於敏感革蘭氏陰性桿菌所致的敗血症、下呼吸道感染、腹腔和膽道感染、複雜性尿路感染和嚴重皮膚軟組織感染等。

注射用頭孢他啶由葛蘭素史克開發,目前已經進口國內的規格為1.0g,商品名:復達欣/FORTUM。根據查詢中康數據顯示,注射用頭孢他啶2020年國內銷售額約為27.5億元。

截至目前,該藥品研發費用投入約為766萬元人民幣(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account